Mode
Text Size
Log in / Sign up
Phase 4 N=16 Randomized Triple-blind Prevention

Analgesic Efficacy of Intravenous Acetaminophen After Video-assisted Thoracic Surgery

Lung Tumor

Enrolled (actual)
16
Serious AEs
0.0%
Results posted
May 2017
Primary outcome: Primary: Total Morphine Consumption (mg) — 34.5; 44 mg

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
IV Acetaminophen (Drug); Saline Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Weill Medical College of Cornell University
Primary completion
Feb 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Total Morphine Consumption (mg)
34.5; 44
SECONDARY
Total Number of PCA Requests in First 24 Hours Post-Operation
41; 43
SECONDARY
VAS Pain Score 2 Hours Post Operation
75.5; 49
SECONDARY
VAS Pain Score 6 Hours Post-Operation
68.5; 39
SECONDARY
VAS Score 24 Hours Post-Operation
53; 16.5

Summary

We will study the efficacy of FDA approved intravenous (IV) acetaminophen ("Ofirmev", © 2011 Cadence Pharmaceuticals, Inc.) in reducing opioid consumption after minimally invasive thoracic surgery in a double blind randomized trial. This drug has been shown in Europe to reduce the need for patient controlled analgesia and the total dose of opioids, which have serious side effects in thoracic surgery patients. We will compare the use of IV patient-controlled morphine (PCA) in two groups of subjects in treating postoperative pain. We will determine if IV acetaminophen reduces post-operative morphine requirements (primary end point). We will also assess subject pain scores and post-operative complications associated with pain management as secondary end points. Our hypothesis is that the study arm receiving intravenous acetaminophen will have lower total morphine consumptions compared to the placebo group.

Eligibility Criteria

Inclusion Criteria

  • Any elective VATS patients with low probability of conversion to thoracotomy as determined by surgery.
  • Ages 18-99
  • American Society of Anesthesiologists Physical Status I-III, hemodynamically stable
  • Male or female

Exclusion Criteria

  • Age less than 18.
  • Patient refusal
  • High probability of conversion to thoracotomy as determined by surgeon
  • Conversion of procedure to thoracotomy (subjects will be withdrawn if VATS procedure is converted to thoracotomy, as thoracotomy is more invasive and will likely require additional analgesia such as neuraxial and regional anesthesia).
  • Scheduled procedure of VATS Pleurodesis/decortication
  • History of Interstitial Lung Disease
  • Emergency case
  • Known allergy/adverse reaction to acetaminophen, morphine, or fentanyl
  • History of drug or alcohol abuse
  • Patients on preoperative analgesic therapy within one week of surgery
  • Contraindication to self administered morphine (unable to understand PCA)
  • Need for postoperative mechanical ventilation
  • Necessary major deviation for intraoperative study protocol as per the discretion of the intraoperative attending anesthesiologist
  • History of congestive heart failure, renal failure, liver failure
  • Pregnant or breastfeeding women
  • Weight less than 51 kg
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01783236). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search